Skip to main content
Premium Trial:

Request an Annual Quote

Celera Added to Nasdaq Biotech Index; Decode, Orchid Bounced

NEW YORK (GenomeWeb News) – Nasdaq announced that it has completed its semi-annual ranking of the Nasdaq Biotechnology Index, and as a result Celera will be added to the index as of the opening of trade on Nov. 24.
 
While Celera was added, Decode Genetics and Orchid Cellmark have been dropped from the index.
 
The Nasdaq Biotech Index is ranked on a semi-annual basis in May and September. Firms must meet certain classification criteria and must be listed on the Nasdaq Global Market or Nasdaq Global Select Market. They also must meet minimum requirements for market value, average daily share volume, and seasoning as a public company.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.